Literature DB >> 17075295

Salivary mucoepidermoid carcinoma: revisited.

Mario A Luna1.   

Abstract

Mucoepidermoid carcinoma (MEC) is a malignant epithelial neoplasm composed of varying proportions of mucous, epidermoid, intermediate, columnar, and clear cells and often demonstrates prominent cystic growth. MEC is usually subclassified as low, intermediate, or high grade on the basis of its histologic features, including the presence of cystic spaces, cellular differentiation, proportion of mucous cells, growth pattern, type of invasion, and cytologic atypia. Because even low-grade neoplasms may metastasize, the term mucoepidermoid tumor is inappropriate. The 3-level grading approach to tumor classification has found general acceptance among pathologists; differences in biologic behavior can be demonstrated even though clinical stage has become a better prognosticator. However, in the case of MEC, no universal agreement exists regarding which histologic grading criteria are most the useful, and grading has varied. These issues have led to the investigation of more subjective systems. We describe these new schemes, the histologic variants of MEC, and the ancillary methods that allow for further stratification of patients with MEC, especially for patients with grade 2 tumors, which have a variable and unpredictable clinical course.

Entities:  

Mesh:

Year:  2006        PMID: 17075295     DOI: 10.1097/01.pap.0000213058.74509.d3

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  36 in total

1.  Fusion proteins in head and neck neoplasms: Clinical implications, genetics, and future directions for targeting.

Authors:  Derek A Escalante; He Wang; Christopher E Fundakowski
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

Review 2.  Genetic alterations in salivary gland cancers.

Authors:  Linda X Yin; Patrick K Ha
Journal:  Cancer       Date:  2016-02-29       Impact factor: 6.860

3.  A clear cell variant of mucoepidermoid carcinoma harboring CRTC1-MAML2 fusion gene found in buccal mucosa: report of a case showing a large clear cell component and lacking typical epidermoid cells and intermediate cells.

Authors:  Shogo Tajima; Ichiro Namiki; Kenji Koda
Journal:  Med Mol Morphol       Date:  2015-08-22       Impact factor: 2.309

Review 4.  Ceruminous Neoplasms of the Ear.

Authors:  Priyadharsini Nagarajan
Journal:  Head Neck Pathol       Date:  2018-08-01

5.  Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis.

Authors:  Nicole A Cipriani; Jonathan J Lusardi; James McElherne; Alexander T Pearson; Andrea D Olivas; Carrie Fitzpatrick; Mark W Lingen; Elizabeth A Blair
Journal:  Am J Surg Pathol       Date:  2019-07       Impact factor: 6.394

6.  A Call for Universal Acceptance of the Milan System for Reporting Salivary Gland Cytopathology.

Authors:  Eric Barbarite; Sidharth V Puram; Adeeb Derakhshan; Esther D Rossi; William C Faquin; Mark A Varvares
Journal:  Laryngoscope       Date:  2019-03-08       Impact factor: 3.325

7.  Overall and cause-specific survival for mucoepidermoid carcinoma of the major salivary glands: Analysis of 2210 patients.

Authors:  Zachary C Taylor; Erin A Kaya; Jeffrey D Bunn; Zachary D Guss; Brian J Mitchell; Robert K Fairbanks; Wayne T Lamoreaux; Aaron E Wagner; Ben J Peressini; Christopher M Lee
Journal:  World J Clin Oncol       Date:  2020-12-24

8.  Mucoepidermoid carcinoma with spindle cell change: a low-grade lesion potentially mistaken for sarcomatoid dedifferentiation.

Authors:  Fumio Ide; Kenji Mishima; Ichiro Saito
Journal:  Head Neck Pathol       Date:  2008-06-24

Review 9.  Molecular heterogeneity in mucoepidermoid carcinoma: conceptual and practical implications.

Authors:  Diana Bell; Adel K El-Naggar
Journal:  Head Neck Pathol       Date:  2013-03-05

10.  Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma.

Authors:  Hyunseok Kang; Marietta Tan; Justin A Bishop; Siân Jones; Mark Sausen; Patrick K Ha; Nishant Agrawal
Journal:  Clin Cancer Res       Date:  2016-06-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.